Claims
- 1. A method of inhibiting or suppressing viral replication in a host cell infected with a virus, comprising the step of administering to the host cell a compound capable of interfering with the binding of at least one C-X-C chemokine with at least one C-X-C chemokine receptor.
- 2. The method of claim 1, wherein the compound is an antibody.
- 3. The method of claim 2, wherein the antibody binds to a C-X-C chemokine.
- 4. The method of claim 3, wherein the antibody is anti-IL-8, anti-GRO-α or anti-IP-10.
- 5. The method of claim 2, wherein the antibody binds to a C-X-C chemokine receptor.
- 6. The method of claim 5, wherein the antibody is anti-CXCR1, anti-CXCR2, or anti-CXCR3.
- 7. The method of claim 1, wherein the compound is a small molecule inhibitor.
- 8. The method of claim 7, wherein the small molecule inhibitor is SB225002.
- 9. The method of claim 1, wherein the compound is a peptide.
- 10. The method of claim 9, wherein the peptide is antileukinate.
- 11. The method of claim 1, wherein the virus is HIV.
- 12. The method of claim 1, wherein the virus is KSHV.
- 13. A method of treating a patient having a viral infection, comprising the step of administering to the patient a compound capable of interfering with the binding of at least one C-X-C chemokine with at least one C-X-C chemokine receptor.
- 14. The method of claim 13, wherein the compound is an antibody.
- 15. The method of claim 14, wherein the antibody binds to a C-X-C chemokine.
- 16. The method of claim 14, wherein the antibody is anti-IL-8, anti-GRO-α, or anti-IP-10.
- 17. The method of claim 14, wherein the antibody binds to a C-X-C chemokine receptor.
- 18. The method of claim 17, wherein the antibody is anti-CXCR1, anti-CXCR2, or anti-CXCR3.
- 19. The method of claim 13, wherein the compound in a small molecule inhibitor.
- 20. The method of claim 19, wherein the small molecule inhibitor is SB225002.
- 21. The method of claim 13, wherein the compound is a peptide.
- 22. The method of claim 21, wherein the peptide is antileukinate.
- 23. The method of claim 13, wherein the viral infection is caused by HIV.
- 24. The method of claim 13, wherein the viral infection is caused by KSHV.
- 25. A method of inhibiting or suppressing viral replication in a host cell infected with a virus, comprising the step of administering to the host cell a compound capable of inhibiting or suppressing expression of at least one C-X-C chemokine.
- 26. The method of claim 25, wherein the compound is an antisense nucleic acid molecule.
- 27. The method of claim 25, wherein the compound is a vector comprising a gene encoding dominant mutant inactive form of the C-X-C chemokine.
- 28. The method of claim 25, wherein the C-X-C chemokine is IL-8, GRO-α or IP-10.
- 29. The method of claim 25, wherein the virus is HIV.
- 30. The method of claim 25, wherein the virus is KSHV.
- 31. A method of inhibiting or suppressing viral replication in a host cell infected with a virus, comprising the step of administering to the host cell a compound capable of inhibiting or suppressing expression of at least one C-X-C chemokine receptor.
- 32. The method of claim 31, wherein the compound is an antisense nucleic acid molecule.
- 33. The method of claim 31, wherein the compound is a vector comprising a gene encoding dominant mutant inactive form of the C-X-C chemokine receptor.
- 34. The method of claim 31, wherein the C-X-C chemokine receptor is CXCR1, CXCR2 or CXCR3.
- 35. The method of claim 31, wherein the virus is HIV.
- 36. The method of claim 31, wherein the virus is KSHV.
- 37. A method of treating a patient having a viral infection, comprising the step of administering to the patient a compound capable of inhibiting or suppressing expression of at least one C-X-C chemokine.
- 38. The method of claim 37, wherein the compound is an antisense nucleic acid molecule.
- 39. The method of claim 37, wherein the compound is a vector comprising a gene encoding for a dominant mutant inactive form of the C-X-C chemokine.
- 40. The method of claim 37, wherein the C-X-C chemokine is IL-8, GRO-α or IP-10.
- 41. The method of claim 37, wherein the viral infection is caused by HIV-1.
- 42. The method of claim 37, wherein the viral infection is caused by KSHV.
- 43. A method of treating a patient having a viral infection, comprising the step of administering to the patient a compound capable of inhibiting or suppressing expression of at least one C-X-C chemokine receptor.
- 44. The method of claim 43, wherein the compound is an antisense nucleic acid molecule.
- 45. The method of claim 43, wherein the compound is a vector comprising a gene encoding for a dominant mutant inactive form of the C-X-C chemokine receptors.
- 46. The method of claim 43, wherein the C-X-C chemokine receptor is CXCR1, CXCR2 or CXCR3.
- 47. The method of claim 43, wherein the viral infection is caused by HIV-1.
- 48. The method of claim 43, wherein the viral infection is caused by KSHV.
SPONSORSHIP
[0001] Work on this invention was sponsored in part by National Institutes of Health Grant AI36685. The Government may have certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60235634 |
Sep 2000 |
US |